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In Scandinavia no large audits of hospitalizations for chronic obstructive pulmonary disease
(COPD) have been performed, and data on adherence to national guidelines are scarce. The
aims of the present study were to audit hospitalizations for COPD exacerbations in three Scan-
dinavian hospitals with respect to incidence, patient population and standards of hospital
care.
Retrospectively all hospitalizations in the Departments of Internal and Respiratory Medicine
in O¨stersund Hospital (Sweden), Aalesund Hospital (Norway) and Trondheim University Hospital
(Norway) from Jan 1 to Dec 31, 2005, with discharge ICD-10 diagnoses J43eJ44, J96 þ J44 or
J13-18 þ j44 were registered. A total of 1144 admissions (731 patients) were identified from
patient administrative systems and medical charts.
Among the admitted patients 27% were >80 years old, >50% had COPD stage III or IV, and 14%
had respiratory acidosis at admittance. Patients with 3 or more admissions (13%) during 2005
accounted for 36% of all hospitalizations. One third of the patients were current smokers.
Non-invasive ventilation was used in 14% of the admissions, with large variation between
centres. In-hospital mortality was 3.7%.
In this first large Scandinavian audit of COPD-hospitalizations, all centres had low in-hospital
mortality. We consider this as an indication of good clinical practice in the three studied
centres and possibly due to the frequent use of non-invasive ventilation.
ª 2010 Elsevier Ltd. All rights reserved.ent of Respiratory Medicine and Allergy, O¨stersund Hospital, 83183 O¨stersund, Sweden. Tel.: þ46 63
ll.se (N. Stenfors).
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Audit of Scandinavian COPD-hospitalizations 1305Background and aims discharged in 2005 with one of the following ICD-10Chronic obstructive pulmonary disease (COPD) is a preva-
lent disease and is expected globally to be the third leading
cause of death by 2030.1 COPD patients experience
frequent exacerbations, and severe exacerbations
requiring hospitalization are associated with significant in-
hospital and post-discharge mortality.2e6 The annual rate
of hospitalizations for COPD is about 200/100,000 in
Sweden7 and 400/100,000 in USA.8 Hospitalizations are
significant contributors to costs related to COPD.9
No large audits of hospitalizations for COPD have been
performed in Scandinavia, and data on adherence to
national guidelines are scarce. Audits in The United
Kingdom (UK), USA and Australia have shown large varia-
tions in in-hospital care for COPD exacerbations.2,3,10e13
Although there are some differences in the organization
of care, the health care systems in Sweden and Norway
have similar funding with public hospitals, and in-patient
treatment is free of charge. National guidelines for
prevention, treatment and care for COPD patients exist in
both Sweden and Norway.14,15
The aims of the present study were to audit hospitali-
zations for COPD exacerbations in three Scandinavian
hospitals with respect to incidence, patient population and
standards of hospital care.
Methods
A retrospective study was conducted of all hospitalizations
for COPD exacerbations from Jan 1 to Dec 31, 2005 in the
Departments of Internal and Respiratory Medicine in
Trondheim University Hospital (Norway), Aalesund Hospital
(Norway), and O¨stersund Hospital (Sweden).
Trondheim University Hospital is the main hospital in mid-
Norway with both a local and regional catchment area. It has
a respiratory department with an intermediate respiratory
care unit where non-invasive ventilation (NIV) is adminis-
tered. Aalesund Hospital is a regional hospital, and patients
with respiratory diseases are admitted to a ward for general
Internal medicine. NIV is administered on the ward or in the
intensive care unit. In Norway patients are usually evaluated
by a general practitioner before admittance to in-hospital
care. O¨stersund Hospital is the only hospital in the county
and has its own respiratory ward. NIV is exclusively given at
the intensive care unit. In Sweden patients are not required
to consult primary health care before seeking emergency
care and hospital admittance. Additional description of the
participating centres is presented in Table 1.
Cases were identified from patient administrative
systems and medical charts were reviewed by the authors
or a medical student. Study inclusion criteria were patientsTable 1 Participating hospitals.
Trondheim (n)
Population 229,096
Hospital beds 1053
ICU beds 12
Respiratory consultants 9discharge diagnoses: I) main diagnoses J43eJ44 (emphy-
sema and chronic obstructive pulmonary disease), irre-
spective of secondary diagnosis, II) main diagnosis J96
(respiratory insufficiency) þ secondary diagnosis J44, or III)
main diagnosis J13-18 (pneumonia) þ secondary diagnosis
J44. Inclusion criteria II and III were used to avoid case
selection bias between the three centres. The coding
practice varied between the three centres due to local
tradition and differences in reimbursement systems.16
During review of medical charts, cases with no evidence
of COPD, ie misdiagnosis, were excluded.
Study variables were chosen in order to audit patient
characteristics, in-hospital care and in-hospital outcomes
and were based on previous international audits and
national clinical guidelines. Study variables and proportion
of missing data are presented in Table 2.
Statistical analyses were performed with STATISTICA
data analysis software system, version 9.0, StatSoft, Inc.
ANOVA was used to compare differences in patient age and
length of stay between hospitals. Pearson Chi2-test was
used to compare differences between centres regarding
categorical variables. To compare the crude- and age-
adjusted incidence between centres a 2-sample test for
equality of proportions with continuity correction was done
using R: A language and environment for statistical
computing, version 2.9.2.16 A p-value <0.01 was considered
statistically significant.
Results
In total, 20 cases were excluded from analysis due to
misdiagnosis. A total of 1144 admissions (731 patients) were
included in the study (Table 3). The distribution (number
and percentage) of patients with the three main discharge
diagnoses were 753 (66%) with J43eJ44, 78 (7%) with
J96 þ J44, and 313 (27%) with J13-18 þ J44, respectively.
The patient mean (SD) age was 73.0 (10.0) years,
without any significant differences between the centres. In
27% of the admissions, the patient’s age was above 80
years. In 92% of the cases, the patient was living at home.
Patients with 3 or more admissions (13%) during 2005
accounted for 36% of all hospitalizations. There were
significant differences between the centres with respect to
the distribution of GOLD stage with the highest percentage
of stage IV patients in O¨stersund (35%) compared to 25% in
Trondheim and 12% in Aalesund. In total, 14% of the
patients had respiratory acidosis at admittance. More
characteristics on patient status at admittance are pre-
sented in Table 3.
The most common COPD-related medication at
admittance was inhaled anticholinergics, which was usedAalesund (n) O¨stersund (n)
91,703 127,424
348 325
10 8
1 5
Table 2 Recorded variables and the amount of missing data.
Variable Categories Missing data (%)
Admittance status Age Years 0
Gender Male, female 0
Referral for admittance None,a primary care,
respiratory specialist, other
11.2
Social status Home, institutionalized 0.7
Number of previous COPD-
hospitalization at same hospital
0, 1e2, >2 0.2
Pre-admission spirometry accessible
in patient medical record
Yes, no 28
Pre-admission GOLDb-stage I, II, III, IV 28
Smoker Current, ex-smoker,
never smoker
4.8
Arterial blood gas Yes, no 18.8
Leg oedema Yes, no 14.6
COPD-related medication
at admission
Inhaled anticholinergics Yes, no 1.0
Short acting b2 agonist Yes, no 1.0
Long acting b2 agonist Yes, no 1.0
Inhaled corticosteroids Yes, no 1.0
Fixed combination inhaled
corticosteroids þ long acting b2 agonist
Yes, no 1.0
Theophylline Yes, no 1.0
Oral steroids Yes, no 0.8
Long term oxygen therapy Yes, no 0.3
In-hospital care Electrocardiogram Yes, no 1.7
Spirometry Yes, no, GOLDb-stage 0.3
Treatment with antibiotics Yes, no 0.5
Treatment with systemic steroids Yes, no 1.0
Treatment with oxygen therapy Yes, no 13.8
Chest x-ray Yes, no 0.1
Physiotherapy Yes, no 1.9
Non-invasive ventilation Yes, no 0.3
Invasive ventilation Yes, no 0.3
Discharge information Length of stay Days 0
In-hospital mortality Yes, no 0
a Patient seeks emergency care without prior contact with health care.
b Global Initiative for Chronic Obstructive Lung Disease.
1306 E.D. Liaaen et al.by 67% of the patients (Table 4). In 18% of the admit-
tances, patients were on long-term oxygen therapy
(LTOT). More data on medication at admittance are
presented in Table 4.
In all three centres, 3% of the admissions required the
use of invasive ventilation. The use of NIV varied signifi-
cantly between the three centres, from 8% to 22% (Table 5).
In 9% of the cases no chest x-ray was done. Chest x-ray
revealed a pulmonary infiltrate in 61% and no pulmonary
infiltrate in 30%of the cases. Fourteen percent of the cases
with main ICD-10 discharge code J43eJ44 had a pulmonary
infiltrate on chest X-ray, whereas 29% of those with main
discharge code J13-18 had no pulmonary infiltrate.
Spirometry during hospitalisation was done in 22% of the
admissions. Data on pre-admission GOLD stage was lacking
in 28% of all cases. In 19% of all admissions, the patient was
discharged without any knowledge of her previous or
present lung function. Additional data on in-hospital care
are presented in Table 5.The overall in-hospital mortality was 3.7% and the mean
(SD) length of stay was 8.6 (8.2) days, with no statistical
differences between the centres. In 25% of the cases the
length of stay was longer than 10 days.
Discussion
Key results
In the present study, COPD-exacerbations requiring hospi-
talizations in three hospitals in Norway and Sweden were
audited. A total of 1144 medical charts from 731 patients
discharged with ICD10-diagnoses J43eJ44, J96 þ J44 or
J13-18 þ j44 during 2005 were reviewed. To the best of our
knowledge, the present study is the first large clinical audit
of Scandinavian COPD-hospitalizations.
In the present audit the patients were elderly and
equally distributed between genders. In one third of the
Table 3 General data and patient status at admittance.
Trondheim Aalesund O¨stersund Total p-value
Hospitalizations (n) 559 260 325 1144
Frequency of admittance
(/100,000 aged  40 years)
539 610 471 531 a
Crude frequency of admittance (/100,000) 244 284 255 255 b
Female (%) 53 35 53 49 0.000
Age (%) <50 3 3 0 2 0.011
50e59 8 7 7 8
60e69 20 21 28 22
70e79 43 38 39 41
>80 26 31 26 27
Current smoker (%) 35 35 25 32 0.000
Number of previous COPD-hospitalization
at same hospital (%)
None 23 27 24 24 0.000
1e2 22 24 24 23
3 55 49 49 52
GOLD stage based on previous spirometry (%) IeII 21 25 8 18 0.000
III 32 36 19 30
IV 24 12 35 24
Respiratory acidosis (%)c 13 10 9 12 0.035
Leg oedema (%) 18 28 25 22 0.010
Referral for admittance (%) Noned 14 14 65 31 <0.001
Primary physician 78 72 23 59
Pulmonary physician 3 8 10 6
Other 5 5 1 4
a Trondheim vs. Aalesund p Z 0.11, Trondheim vs. O¨stersund p Z 0.056, Aalesund vs. O¨stersund p Z 0.002.
b Trondheim vs. Aalesund p Z 0.049, Trondheim vs. O¨stersund p Z 0.55, Aalesund vs. O¨stersund p Z 0.22.
c Patient seeks emergency care without prior contact with health care.
d pH & 7.35, pCO2 > 6 kPa.
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severe COPD, as well as patients with frequent admissions
accounted for a significant proportion of the hospitaliza-
tions. Non-invasive ventilation was frequently used, with
large variation between centres. All three centres had low
in-hospital mortality.
Study limitations
The present study design is associated with some limita-
tions that may have affected the study results.
Firstly, medical records with main discharge diagnoses
J43eJ44, J96þ J44 or J13-18þ j44 were included. These are
common combinations used in Scandinavia for COPD exacer-
bations. Inclusion of admissions with pneumonia as mainTable 4 COPD-related medication at admittance.
Trondheim (%) Aale
Short acting b2 agonist 68 64
Long acting b2 agonist 10 7
Inhaled corticosteroid 15 14
Fixed combination inhaled
corticosteroid þ long acting
b2 agonist
47 55
Theophylline 14 25
Oral steroid 34 41diagnosis and COPD as secondary diagnosis might increase the
heterogeneity of the material, but it reduces the risk of case
selection bias between the three centres. However, it is
possible that the present study cohort including COPD-
exacerbation with pneumonia represent a population with
higher morbidity compared to a large US COPD audit, where
cases with pneumonia as secondary diagnosis were excluded.2
Secondly, as very few cases of COPD exacerbations were
managed outside the Medical or Pulmonary Departments,
admissions to other departments were not reviewed.
Thirdly, interpretation of historical data will always be
limited by a certain degree of missing data. The collection
of historical data from medical records relies on good
medical documentation. In particular, absence of docu-
mentation does not necessarily mean absence of process.sund (%) O¨stersund (%) Total (%) P-value
56 64 0.001
20 12 0.000
35 20 0.000
40 47 0.002
11 16 0.000
24 33 0.000
Table 5 In-hospital management.
Trondheim (%) Aalesund (%) O¨stersund (%) Total (%) P-value
Non-invasive ventilation 14 22 8 14 0.000
Antibiotics 68 71 60 66 0.007
Systemic steroids 83 77 78 80 0.086
Chest x-ray 98 97 75 91 0.000
Electrocardiography 80 77 72 77 0.010
Arterial blood gas 79 89 80 82 0.002
Physiotherapy 19 23 10 18 0.000
Oxygen therapy 94 85 86 89 0.000
1308 E.D. Liaaen et al.However, taking into account the increasing demands from
the health authorities on medical documentation during the
last decade, the authors believe that in the present study
the proportion of missing data is relatively low.
Interpretation
In Trondheim and O¨stersund the patients were equally
distributed between genders. However, in Aalesund,
significantly fewer females than males were admitted to
hospital for COPD. The explanation for this finding is
beyond the scope of this paper and will be addressed in
a future study.
Compared to the Norwegian centres, a smaller propor-
tion of the admitted COPD patients in O¨stersund were
current smokers. This is probably due to the lower preva-
lence of smoking in Sweden. In 2005, the prevalence of
daily smokers was 16% in Sweden versus 25% in Norway.17,18
Frequent hospital admittances are common among COPD
patients. In the present study, patients with three or more
previous COPD-admissions during 2005 (13%) accounted for
36% of all COPD-hospitalizations. Moreover, patients with
no previous COPD-hospitalization accounted for only 24% of
the admittances. Interestingly, a similar proportion (29%)
was found in a UK audit.10
A majority of the admitted patients had severe or very
severe COPD (GOLD III or IV). Moreover, 18% of the admitted
patients had LTOT. In a Danish study from 2000, 16% of the
patients admitted because of COPD had LTOT.19 In an UK
audit on COPD exacerbations published 1997, among the
first time admissions 6% of the patients had LTOT whereas
29% the readmitted patients had LTOT.10
There were significant differences between the centres in
the patients useofCOPDmedicationat admittance. In the two
Norwegian centres, a significantly higher proportion of the
patients had oral steroids at admittance than in O¨stersund.
This difference is probably due to a larger proportion of
Norwegian patients evaluated and treated by a primary care
physician before referral for admittance. In O¨stersund, the
majority of patients came directly to the emergency unit
without prior contact with the primary health care.
NIV was administered in 14% of the COPD-
hospitalizations, with large variations between the
centres. This wide variation may be explained by differ-
ences in the availability of NIV and differences with respect
to adherence to clinical guidelines. In Aalesund, although
only 10% of the cases had respiratory acidosis, 22% of the
admitted patients had been treated with NIV. This liberaluse of NIV was probably due to NIV being easily available at
the ward and thus used more liberally than what is rec-
ommended in most guidelines. In comparison, audits from
UK 1997, US 2001 and Denmark 2000, found that only 3e4%
of the patients admitted for COPD were given ventilatory
assistance.2,10,19
Antibiotics were administered during in-hospital care in
66% of the cases compared to 80e85% found in UK and US
audits.2,10 Moreover, in a smaller Danish study, 53% of the
patients were given antibiotics.19 These between-country
variations are more likely to be explained by differences
in study inclusion criteria and national guidelines than
differences in the prevalence of bacterial infections. As
criteria for antibiotic therapy were not registered in the
present study, the proportion of ideal candidates for anti-
biotic therapy cannot be measured.20
In 20% of the cases, the patient did not receive systemic
steroid treatment during the hospital stay. This may
represent an under treatment of patients hospitalized for
COPD or a result of including patients with mild COPD and
concurrent pneumonia. It could also be due the presence of
diabetes or gastric ulcers which would make the physician
hesitate to use oral steroids.
Ninety-one percent of the cases underwent chest radi-
ography which is in keeping with the findings from a large
US audit where 95% of the patients had a chest radiography
done.2 In an UK audit of cases admitted for COPD,
a comment on the chest radiograph was recorded within
the first 24 h in 65% of the admissions.10 Surprisingly, among
those with main discharge code J13-18, 29% had no
pulmonary infiltrate, and among those with main discharge
code J43eJ44 a pulmonary infiltrate was found in 14% of
the cases. This finding demonstrates the heterogeneity of
COPD hospitalizations and further underlines the need for
standardized coding procedures in order to make interna-
tional comparisons.
In as many as 28% of all cases no data on pre-admission
disease stage was found and only in 22% of the cases was
a spirometry performed during the hospital stay. One may
argue that knowledge of patient’s lung function is vital in
all admissions for COPD. Despite this, 19% of all patients
were discharged without any accessible spirometry data. In
an US audit, spirometry was considered a non-beneficial
measure and was done in only 12% of all admissions for
COPD exacerbation.2 In the UK, where guidelines recom-
mend confirmation of a clinical diagnosis with spirometry,
Roberts et al. found that only 53% of the cases had FEV1
documented 5 years prior or 3 months post-discharge.10 In
Audit of Scandinavian COPD-hospitalizations 1309the present study twice as many patients were given
physiotherapy (18%) compared to an US study from 2001
where only 6.2% of the patients received physiotherapy.2
In the present study mean length of hospital stay was 8.6
days. In comparison, audits from UK, US and Denmark have
found in-hospital stays from 5.3 to 9.9 days.2,3,19 All three
centres had low in-hospital mortality (3.7%). An UK audit
from 2003, an US audit from 2001, and a Danish audit from
2000 found an in-patient mortality of 7.4%,3 4.4%,2 and
9%,19 respectively. The liberal use of NIV may partly explain
the lower in-hospital mortality found in the present study,
but this needs to be further elucidated.
Generalisability, implications and opportunities for
improvement
The authors believe that many of the presented results may
be generalised to other centres, at least in the Scandina-
vian countries where by large the health care systems are
organized equally. Furthermore, the present audit provides
data for national and international comparisons as well as
longitudinal follow-up studies.
The study results have provided important information
for immediate improvement of the clinical care at the
participating centres. Like what has been found in previous
audits, a significant number of COPD patients were dis-
charged without any medical record documentation of their
lung function. This is a challenge to many centres where
patients with COPD exacerbations are being treated. An
increased focus on early discharge schemes and integrated
follow-up strategies will probably have the potential to
reduce the length of stay and the frequency of COPD
hospitalizations, and thus reduce the costs of hospital care.Acknowledgements
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